David W Goodrich
Overview
Explore the profile of David W Goodrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
2907
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lama R, Wu W, Mavis C, Ruiz F, Querol-Garcia J, Martin D, et al.
Front Oncol
. 2025 Jan;
14:1462231.
PMID: 39763603
Rituximab combined with systemic chemotherapy significantly improves the rate of complete response in B-cell lymphomas. However, acquired rituximab resistance develops in most patients leading to relapse. The mechanisms underlying rituximab...
2.
Cordova R, Sommers N, Law A, Klunk A, Brady K, Goodrich D, et al.
Sci Signal
. 2024 Nov;
17(864):eadp1375.
PMID: 39591412
Cancers invoke various pathways to mitigate external and internal stresses to continue their growth and progression. We previously reported that the eIF2 kinase GCN2 and the integrated stress response are...
3.
Chatterjee S, Linares J, Cid-Diaz T, Duran A, Khan M, Osrodek M, et al.
Nat Commun
. 2024 Nov;
15(1):9755.
PMID: 39567499
Overcoming resistance to therapy is a major challenge in castration-resistant prostate cancer (CRPC). Lineage plasticity towards a neuroendocrine phenotype enables CRPC to adapt and survive targeted therapies. However, the molecular...
4.
Ku S, Wang Y, Garcia M, Yamada Y, Mizuno K, Long M, et al.
J Clin Invest
. 2024 Jul;
134(17).
PMID: 39024561
Notch signaling can have either an oncogenic or tumor-suppressive function in cancer depending on the cancer type and cellular context. While Notch can be oncogenic in early prostate cancer, we...
5.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(28):e2322203121.
PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
6.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
7.
Miller K, Degan S, Wang Y, Cohen J, Ku S, Goodrich D, et al.
Oncogene
. 2023 Dec;
43(1):76.
PMID: 38097735
No abstract available.
8.
Miller K, Degan S, Wang Y, Cohen J, Ku S, Goodrich D, et al.
Oncogene
. 2023 Oct;
43(1):22-34.
PMID: 37875657
PTEN loss, one of the most frequent mutations in prostate cancer (PC), is presumed to drive disease progression through AKT activation. However, two transgenic PC models with Akt activation plus...
9.
Patel R, Sayar E, Coleman I, Roudier M, Hanratty B, Low J, et al.
J Pathol
. 2023 Oct;
262(1):105-120.
PMID: 37850574
HOXB13 is a key lineage homeobox transcription factor that plays a critical role in the differentiation of the prostate gland. Several studies have suggested that HOXB13 alterations may be involved...
10.
Zhang L, Liu C, Zhang B, Zheng J, Singh P, Bshara W, et al.
J Thorac Oncol
. 2022 Dec;
18(3):324-338.
PMID: 36473627
Introduction: High-grade neuroendocrine tumors of the lung such as SCLC are recalcitrant cancers for which more effective systemic therapies are needed. Despite their histopathologic and molecular heterogeneity, they are generally...